Effect of levodopa on interleukin-15 and RANTES circulating levels in patients affected by Parkinson's disease.
Parkinson's disease (PD) is an extra-pyramidal neurodegenerative disorder, in which alterations of the immune system are involved. Interleukin (IL)-15 stimulates cellular immune response and induces growth and differentiation of various immune cells. RANTES, promoting leukocyte infiltration to sites of inflammation, mediates the trafficking and homing of immune cells. To clarify the potential effect of levodopa on the immunological network of PD, we analyzed IL-15 and RANTES serum levels in PD patients, treated or not with levodopa, and in healthy donors. Levodopa-treated patients showed significantly higher IL-15 and RANTES circulating levels with respect to healthy controls and higher, although not significantly, levels with respect to untreated patients. So, we hypothesize that the immunological alterations found in PD may be linked, at least in part, to levodopa therapy.
D000368:Aged; D000978:Antiparkinson Agents / Q000276:immunology* / Q000627:therapeutic use; D018946:Chemokine CCL5 / Q000097:blood* / Q000276:immunology; D005260:Female; D006801:Humans; D019409:Interleukin-15 / Q000097:blood* / Q000276:immunology; D007980:Levodopa / Q000276:immunology* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000097:blood* / Q000188:drug therapy / Q000276:immunology*
D000978:Antiparkinson Agents; D018946:Chemokine CCL5; D019409:Interleukin-15; D007980:Levodopa